Highest-materiality recent filing
Ocular Therapeutix Q2 2026 net loss $78.8M; AXPAXLI NDA on track for Q4 2026
Net loss of $78.8M ($0.35 per share) for Q2 2026, vs. $67.8M loss in Q2 2025.
Jason Robins, interim CFO since Jan 2026, appointed permanent CFO; salary raised to $535,100 effective July 1, 2026, plus stock option and RSU grants.
Ocular Therapeutix Q1 net loss $88.6M; cash $666.7M; AXPAXLI NDA on track with SOL-1 data
Net loss $88.6M ($0.40 per share) vs $64.1M ($0.38) in Q1 2025; revenue $10.8M, up 0.8%.
Slides from 49th Macula Society Annual Meeting on Feb 27, 2026 posted on investor website.
Ocular Therapeutix Q4 net loss $0.29/shr; SOL-1 data readout at Macula Society Feb 25-28
Q4 2025 net revenue $13.3M, down 22.4% YoY; full year $52.0M, down 18.5%.
Effective Jan 20, 2026, CFO/COO Donald Notman on temporary leave; Jason Robins named interim CFO and principal financial/accounting officer.
Ocular Therapeutix to submit AXPAXLI NDA based on SOL-1 year 1 data after FDA flexibility signal
FDA signals may allow single pivotal trial for AXPAXLI in wet AMD, changing prior two-trial requirement.
Ocular Therapeutix Q3 net loss $69.4M; SOL-R hits 555 subjects; cash ~$790M with offering
Net loss $(69.4)M ($0.38 loss per share) vs $(36.5)M loss in Q3 2024; revenue $14.5M, down 5.8% YoY.
Ocular Therapeutix prices $475M common stock offering at $12.53/share to fund AXPAXLI trials
Offering of 37,909,018 shares priced at $12.53 each for gross proceeds ~$475M; net proceeds ~$445.9M.
Ocular Therapeutix Q2 revenue falls 18% to $13.5M; net loss $67.8M; SOL-1 data Q1 2026
Q2 net revenue $13.5M, down 18% YoY; DEXTENZA unit sales up 5% but net revenue pressured by reimbursement challenges.
SOL-R enrollment complete; shareholders approve 8.75M share increase and CEO award
SOL-R Phase 3 trial for AXPAXLI (wet AMD) completed enrollment on May 31, 2025; target randomization of at least 555 subjects.
Ocular Therapeutix Q1 net revenue down 27.6% to $10.7M; cash $349.7M, runway to 2028
Net loss of $64.1M ($0.38 per share) vs. $64.8M ($0.49) in Q1 2024; R&D expenses doubled to $42.9M on wet AMD trials.
Q4 2024 revenue $17.1M (+15.4% YoY); FY2024 revenue $63.7M (+9.0% YoY). Net loss $(193.5)M for FY2024 vs $(80.7)M in FY2023.
CEO Dugel receives new compensation package with $819,200 salary, performance stock awards
Base salary raised to $819,200 annually; bonus target at 75% of salary; $368,100 2024 bonus plus $500,000 special one-time bonus.
Ocular Therapeutix Q3 net loss $36.5M; SOL-1 topline data expected Q4 2025
Net loss of $36.5M ($0.22 diluted EPS) vs $0.5M loss in Q3 2023; R&D spend jumped to $37.1M.
Ocular Therapeutix Q2 net loss $(43.8)M; AXPAXLI SOL-R accepted as pivotal trial
Net loss of $(43.8)M ($(0.26)/share) vs $(20.7)M ($(0.26)/share) in Q2 2023; revenue $16.4M (+8.3% YoY).
Ocular Therapeutix Q1 net loss $64.8M ($0.49/sh); revenue $14.8M up 10.4% YoY
Net loss of $64.8M ($0.49/sh) vs $30.3M loss ($0.39/sh) in Q1 2023; includes $28M non-cash loss on debt extinguishment.
Ocular Therapeutix appoints Pravin Dugel as CEO, Nadia Waheed as CMO; stock plan increased
Pravin U. Dugel appointed President and CEO, effective April 14, 2024; he remains Executive Chairman.
Ocular Therapeutix Q4 net loss $29.2M, revenue $14.8M; cash $195.8M plus $325M PIPE
Q4 net loss $29.2M ($0.35 loss per share); revenue $14.8M, up 5% YoY.
Ocular Therapeutix raises $325M in private placement; appoints Pravin Dugel as Executive Chairman
Entered securities purchase agreement for 32.4M shares at $7.52/share and pre-funded warrants for 10.8M shares at $7.519/warrant, gross proceeds ~$325M.
Ocular Therapeutix obtains FDA SPA modification for pivotal Phase 3 AXPAXLI wet AMD trial
FDA agreed to SPA modification for SOL trial evaluating AXPAXLI (axitinib intravitreal implant) for wet AMD.
Ocular Therapeutix prices $100.1M public offering; updates wet AMD trial and cash runway into 2027
Priced underwritten public offering of 30.8M shares at $3.25/share for gross proceeds of $100.1M; net proceeds ~$93.6M.
Ocular Therapeutix Q3: DEXTENZA revenue up 26% YoY to $15M; net loss narrows to $0.5M
DEXTENZA net product revenue $15.0M (+26% vs Q3 2022), in line with Q2 2023; full-year guidance raised to upper end of $55-60M.
Ocular Therapeutix initiates first pivotal trial of OTX-TKI for wet AMD
Activated first US clinical trial site; expects to enroll first subject by year-end 2023.
Ocular Therapeutix submits SPA request to FDA for OTX-TKI pivotal trial in wet AMD
Submitted SPA request for first of two planned pivotal trials of OTX-TKI for wet AMD.
DEXTENZA net product revenue $15.0M in Q2 2023, up 24% from $12.1M in Q2 2022 and 14% sequentially.
Ocular Therapeutix reports positive 12-month Phase 1 data for OTX-TKI in wet AMD
12-month data showed OTX-TKI maintained controlled wet AMD comparable to aflibercept, with mean BCVA change of -1.0 letters vs +2.0 letters.
Ocular Therapeutix Q1 net loss widens to $30.3M; DEXTENZA rev up 6% to $13.2M
Net loss of $30.3M ($0.39/share) vs $12.5M ($0.16/share) in Q1 2022; includes $6.6M non-cash derivative fair value charge.
Ocular Therapeutix Q4 DEXTENZA rev $13.9M (+14% YoY); guides 2023 rev $55-60M; net loss $71M
DEXTENZA net product revenue Q4 2022 $13.9M (+14% YoY, +17% QoQ); full year $50.5M (+20% YoY).
Ocular Therapeutix: 2022 Dextenza revenue est. $50.2M (+20% YoY); cash $102.3M; pipeline on track
Dextenza net product revenue: Q4 2022 est. $13.6M (14% seq., 11% YoY); FY2022 est. $50.2M (20% YoY).
DEXTENZA net product revenue $11.9M in Q3 2022, flat YoY and down ~2% sequentially; 2022 guidance revised to $48-52M (10-20% growth).
Ocular Therapeutix Q2 net product rev $12.1M (+9% YoY); net loss $18.8M; FY guidance reaffirmed
DEXTENZA net product revenue $12.1M in Q2 2022, up 9% YoY from $11.1M; total net revenue $12.3M.
DEXTENZA net product revenue $12.5M in Q1 2022, up 87% from $6.7M in Q1 2021.
Ocular Therapeutix reports Q4 2021 DEXTENZA revenue $12.2M, up 77% YoY; net loss $3.9M
DEXTENZA net product revenue $12.2M in Q4, +77% vs Q4 2020; full year $43.5M vs $17.4M.
On June 10, 2026, the Board appointed Jason Robins, the Company’s interim Chief Financial Officer, to serve as the Chief Financial Officer.
On August 29, 2024, the board of directors of Ocular Therapeutix, Inc. (the “Company”) appointed Donald Notman to serve as Chief Operating Officer of the Company.
On April 14, 2024 (the “Transition Date”), the board of directors of Ocular Therapeutix, Inc. (the “Company”) appointed Pravin U. Dugel, M.D., to serve as President and Chief Executive Officer of the Company.
On the Transition Date, Dr. Dugel succeeded Antony C. Mattessich as the Company’s President and Chief Executive Officer, and Mr. Mattessich resigned from the board of directors of the Company.
Effective upon the commencement of Dr. Waheed’s employment, Rabia Gurses Ozden, M.D., will cease to serve as the company’s Chief Medical Officer.
On April 16, 2024, the Company announced that Nadia Waheed, M.D., had been appointed to serve as Chief Medical Officer of the Company, effective upon the anticipated commencement of her employment with the Company on May 20, 2024.
On February 20, 2024, Pravin U. Dugel, M.D., was appointed as Executive Chairman of the Company and as a Class III director, effective as of February 21, 2024
On July 10, 2023 (the “Effective Date”), the board of directors (the “Board”) of Ocular Therapeutix, Inc., a Delaware corporation (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Adrienne L. Graves, Ph.D., to serve as a member of the Board, effective immediately.
On June 3, 2022, Michael Goldstein, M.D., President, Ophthalmology and Chief Medical Officer of Ocular Therapeutix, Inc. (the “Company”) and the Company mutually agreed that Dr. Goldstein would depart the Company to pursue other business opportunities, effective June 30, 2022 (the “Separation Date”).
In connection with his departure, Rabia Gurses Ozden, M.D., Senior Vice President, Clinical Development of the Company, has agreed to assume the role of Chief Medical Officer of the Company, effective on July 1, 2022.
On February 3, 2022, Bruce A. Peacock notified Ocular Therapeutix, Inc. (the “Company”) that he planned to resign as a member of the Board of Directors on the date of the Company’s annual meeting of stockholders to be held in 2022.
elected Merilee Raines to serve as a member of the Board to fill a vacancy on the Board
Max materiality 0.90 · Median 0.65 · Most common event earnings